Presentation is loading. Please wait.

Presentation is loading. Please wait.

Paul D. Thompson, MD, John Rubino, MD, Matthew J. Janik, MD, Diane E

Published byVarvara Octavia Nistor Modified over 6 years ago

Similar presentations

Presentation on theme: "Paul D. Thompson, MD, John Rubino, MD, Matthew J. Janik, MD, Diane E"— Presentation transcript:

1 Use of ETC-1002 to treat hypercholesterolemia in patients with statin intolerance 
Paul D. Thompson, MD, John Rubino, MD, Matthew J. Janik, MD, Diane E. MacDougall, MS, Scott J. McBride, MA, Janice R. Margulies, MS, Roger S. Newton, PhD  Journal of Clinical Lipidology  Volume 9, Issue 3, Pages (May 2015) DOI: /j.jacl Copyright © 2015 National Lipid Association Terms and Conditions

2 Figure 1 Study design. PBO, placebo.
Journal of Clinical Lipidology 2015 9, DOI: ( /j.jacl ) Copyright © 2015 National Lipid Association Terms and Conditions

3 Figure 2 Patient disposition. Asterisk, based on low-density lipoprotein cholesterol (LDL-C). mITT, modified intent to treat. Journal of Clinical Lipidology 2015 9, DOI: ( /j.jacl ) Copyright © 2015 National Lipid Association Terms and Conditions

4 Figure 3 Least squares (LS) mean percent change from baseline to week 8 in calculated low-density lipoprotein cholesterol (LDL-C) (primary end point). Asterisk, P < .0001 based on analysis of covariance model with effect of treatment and baseline value as a covariate. CI, confidence interval. Journal of Clinical Lipidology 2015 9, DOI: ( /j.jacl ) Copyright © 2015 National Lipid Association Terms and Conditions

5 Figure 4 Changes from baseline in low-density lipoprotein cholesterol (LDL-C), non–high-density lipoprotein cholesterol (HDL-C), and total cholesterol by treatment group. Analysis is based on the completer population for each time point. Asterisk, P ≤ .0001 based on analysis of covariance model with effect of treatment and baseline value as a covariate. PBO, placebo. Journal of Clinical Lipidology 2015 9, DOI: ( /j.jacl ) Copyright © 2015 National Lipid Association Terms and Conditions

6 Figure 5 Patients achieving National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP-III) low-density lipoprotein cholesterol (LDL-C) goal at the end of the study. Analysis included patients not at NCEP ATP-III goal at baseline (n = 34, ETC-1002; n = 17, placebo). Missing values at week 8 were imputed using the last-observation-carried-forward procedure. Asterisk, P < .0001 compared with placebo at week 8 (end of study) based on the Fisher exact test. Journal of Clinical Lipidology 2015 9, DOI: ( /j.jacl ) Copyright © 2015 National Lipid Association Terms and Conditions

Download ppt "Paul D. Thompson, MD, John Rubino, MD, Matthew J. Janik, MD, Diane E"

Similar presentations

Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated.

Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated.
A Multiregional, Randomized Evaluation of the Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients With.

A Multiregional, Randomized Evaluation of the Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients With.
Michael J. Koren, MD, Michael H. Davidson, MD, Daniel J

Michael J. Koren, MD, Michael H. Davidson, MD, Daniel J
Impact of Age and Estimated Glomerular Filtration Rate on the Glycemic Efficacy and Safety of Canagliflozin: A Pooled Analysis of Clinical Studies  Richard.

Impact of Age and Estimated Glomerular Filtration Rate on the Glycemic Efficacy and Safety of Canagliflozin: A Pooled Analysis of Clinical Studies  Richard.
Lipid abnormalities in foreign-born and US-born patients in a medical group  Jawali Jaranilla, MD, MPH, Terese DeFor, MS, Gabriela Vazquez Benitez, PhD,

Lipid abnormalities in foreign-born and US-born patients in a medical group  Jawali Jaranilla, MD, MPH, Terese DeFor, MS, Gabriela Vazquez Benitez, PhD,
Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24week, double-blind, randomized.

Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24week, double-blind, randomized.
A randomized trial evaluating the efficacy and safety of alirocumab in South Korea and Taiwan (ODYSSEY KT)  Kwang Kon Koh, MD, PhD, FACC, Chang Wook Nam,

A randomized trial evaluating the efficacy and safety of alirocumab in South Korea and Taiwan (ODYSSEY KT)  Kwang Kon Koh, MD, PhD, FACC, Chang Wook Nam,
Volume 93, Issue 6, Pages (June 2018)

Volume 93, Issue 6, Pages (June 2018)
Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.

Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.
Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial.

Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial.
An assessment by the Statin Liver Safety Task Force: 2014 update

An assessment by the Statin Liver Safety Task Force: 2014 update
Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: Pooled analysis of eight ODYSSEY.

Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: Pooled analysis of eight ODYSSEY.
Purified palmitoleic acid for the reduction of high-sensitivity C-reactive protein and serum lipids: A double-blinded, randomized, placebo controlled.

Purified palmitoleic acid for the reduction of high-sensitivity C-reactive protein and serum lipids: A double-blinded, randomized, placebo controlled.
Martin W. Schoen, MD, MPH, Joanne Salas, MPH, Jeffrey F

Martin W. Schoen, MD, MPH, Joanne Salas, MPH, Jeffrey F
Efficacy and safety of gemcabene as add-on to stable statin therapy in hypercholesterolemic patients  Evan Stein, MD, Harold Bays, MD, Michael Koren,

Efficacy and safety of gemcabene as add-on to stable statin therapy in hypercholesterolemic patients  Evan Stein, MD, Harold Bays, MD, Michael Koren,
Association of triglyceride-to-high density lipoprotein cholesterol ratio to cardiorespiratory fitness in men  Gloria Lena Vega, PhD, Scott M. Grundy,

Association of triglyceride-to-high density lipoprotein cholesterol ratio to cardiorespiratory fitness in men  Gloria Lena Vega, PhD, Scott M. Grundy,
Emerging LDL therapies: Mipomersen—antisense oligonucleotide therapy in the management of hypercholesterolemia  Peter P. Toth, MD, PhD, FAAFP, FICA, FNLA,

Emerging LDL therapies: Mipomersen—antisense oligonucleotide therapy in the management of hypercholesterolemia  Peter P. Toth, MD, PhD, FAAFP, FICA, FNLA,
Omega-3 carboxylic acids in patients with severe hypertriglyceridemia: EVOLVE II, a randomized, placebo-controlled trial  Erik S.G. Stroes, MD, PhD, Andrey.

Omega-3 carboxylic acids in patients with severe hypertriglyceridemia: EVOLVE II, a randomized, placebo-controlled trial  Erik S.G. Stroes, MD, PhD, Andrey.
Glucagon-like peptide-1 receptor agonists reduced the low-density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus treated with.

Glucagon-like peptide-1 receptor agonists reduced the low-density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus treated with.
Apolipoprotein E-containing high-density lipoprotein (HDL) modifies the impact of cholesterol-overloaded HDL on incident coronary heart disease risk:

Apolipoprotein E-containing high-density lipoprotein (HDL) modifies the impact of cholesterol-overloaded HDL on incident coronary heart disease risk:

Similar presentations

Ads by Google